Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Free Cash Flow (2016 - 2025)

Sangamo Therapeutics has reported Free Cash Flow over the past 16 years, most recently at -$24.4 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$24.4 million for Q4 2025, down 662.63% from a year ago — trailing twelve months through Dec 2025 was -$97.3 million (down 44.39% YoY), and the annual figure for FY2025 was -$97.3 million, down 44.39%.
  • Free Cash Flow for Q4 2025 was -$24.4 million at Sangamo Therapeutics, up from -$28.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for SGMO hit a ceiling of $11.8 million in Q3 2024 and a floor of -$76.5 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$48.7 million (2023), compared with a mean of -$43.4 million.
  • Biggest five-year swings in Free Cash Flow: surged 134.4% in 2024 and later tumbled 662.63% in 2025.
  • Sangamo Therapeutics' Free Cash Flow stood at -$53.6 million in 2021, then crashed by 36.74% to -$73.3 million in 2022, then skyrocketed by 34.2% to -$48.2 million in 2023, then soared by 93.37% to -$3.2 million in 2024, then tumbled by 662.63% to -$24.4 million in 2025.
  • The last three reported values for Free Cash Flow were -$24.4 million (Q4 2025), -$28.5 million (Q3 2025), and -$18.0 million (Q2 2025) per Business Quant data.